Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany
← catalyst calendarNCT06336330 · readout in 134 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
831actual
Sites
47
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-25 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Heart Diseases
- Cardiovascular Diseases
- Heart Failure
Primary outcomes
what the primary-completion date above is the date OFTime to discontinuation of dapagliflozin
measured Baseline to 12 months
Reasons for discontinuation of dapagliflozin
measured Baseline to 12 months
Dose changes of dapagliflozin
measured Baseline to 12 months
Number of patients with dapagliflozin treatment interruptions
measured Baseline to 12 month
Treatment switches from dapagliflozin to other SGLT2i
measured Baseline to 12 months
Time to other heart failure treatment discontinuation
measured Baseline to 12 months
Number of other heart failure treatment initiation
measured Baseline to 12 months
Number of other heart failure treatment dosage changes
measured Baseline to 12 months
Number of other heart failure treatment discontinuation
measured Baseline to 12 months
Number of glucose lowering medication initiation
measured Baseline to 12 months
Number of glucose lowering medication dosage changes
measured Baseline to 12 months
Number of glucose lowering medication discontinuation
measured Baseline to 12 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed